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Keeping time on liver fibrosis
Steven O’Reilly1
Acta Pharmacologica Sinica; https://doi.org/10.1038/s41401-021-00716-2
Liver fibrosis is a common and deadly consequence of repeated
exposure to an insult which can be of varying aetiology
including viral (hepatitis), autoimmune or alcohol misuse. Key
to the disease is the activation of stellate cells that produce a
surfeit of extracellular matrix (ECM) including collagens and
fibronectin and express the contractile protein alpha-smooth
muscle actin. It is now accepted that to activate these key ECM-
producing cells new substrates and energy are needed, through
glycolysis this is performed. Recently, Xu et al demonstrated a
link between phenotypic conversion, glycolysis and the circa-
dian clock [1].
The circadian clock is a cell intrinsic clock that is a
timekeeper. Circadian clocks in the brain and peripheral tissues
temporally coordinate local context to align with the 24-h
rhythmic environment through light/darkness cycles [2]. It is
known in shift workers that they have a higher incidence of
disease, suggesting that disruptions of the circadian clock
mediate disease. Indeed immune cells such as monocytes
and macrophages display a robust molecular clock and at least
8% of transcripts in murine macrophages are circadian [3].
Indeed the time of day that the mice are challenged will
give a divergent response [4]. One key component of the
molecular clock is the transcription factor Brain and Muscle
ARNT-Like 1 (BMAL1). BMAL1 is a transcription factor that binds
with CLOCK to positively regulate circadian genes and
regulate biological functions. This heterodimers also activate
their transcriptional repressors Period1 and Period2 and
Cryptochrome 1 and Crytopchrome 2 (Cry1/2) via a negative
feedback loop
In Xu’s study they demonstrated significantly reduced BMAL1
levels in the classic carbon tetrachloride model of liver fibrosis
in mice–a standard model for in vivo liver fibrosis. They also
showed significant reduction in BMAL1 in vitro in hepatic
stellate cells and in LX-2 cells that the classic fibrotic cytokine
TGF-β1 reduced BMAL1 expression at the protein level
suggesting TGF-β1 is an upstream regulator of BMAL1. Using
an overexpression vector to artificially enhance BMAL1 they
demonstrated downregulation of key glycolysis enzymes
Hexokinase II (HKII) and PKM2 and a subsequent reduction in
the glycolytic rate and finally they demonstrated overexpres-
sion of BMAL1 retarded the phenotypic conversion of the
stellate cells and ECM production.
Furthermore, they found that BMAL1 interacts with the
protein isocitrate dehydrogenase-1 (IDH-1). IDH-1 is the key
enzyme in the decarboxylation of isocitrate to yield α-
ketoglutarate in the TCA cycle. IDH-1 was also reduced by
TGF-β1 treatment in vitro. Overexpression of BMAL1 resulted in
a large increase in IDH-1 and a significant increase in its product
α-ketoglutarate and a concomitant reduction in glycolysis (and
HKII) which could be reversed with small interfering RNA to IDH-
1. Finally using a recombinant adenoviral associated viral system
they overexpressed BMAL1 specifically in hepatocytes and used
the carbon tetrachloride model of fibrosis. This hepatocyte
overexpression of BMAL1 significantly reduced upregulated
glycolysis, reduced key glycolytic enzymes and elevated IDH-1.
Most importantly this retarded liver fibrosis and collagen
deposition are associated with increased α-ketoglutarate.
Because BMAL1 inhibitory effect on glycolysis was abolished
by IDH-1 and therefore α-ketoglutarate silencing, this demon-
strate that α-ketoglutarate is required for BMAL1’s antifibrotic
effect.
How is α-ketogluturate retarding glycolysis? This molecule
normally serves as a precursor for amino acid synthesis and as a
substrate for 2-oxygluturate-dependant dioxygenases which
include epigenetic enzymes that belong to the histone
demethylase family. These histone demethylases remove methyl
marks on histones and thereby regulate gene expression. It
could therefore be speculated that α-ketogluturate increased
expression/activity of histone demethylase enzymes that results
in repression of glycolysis. In respect of a recent study, albeit in
endothelial cells, it was demonstrated that the Jumanji-domain-
containing protein 8 protein, which used α-ketoglutarate as a
substrate, regulated glycolysis by direct regulation of the key
glycolytic enzyme PKM2 [5].
This work demonstrates that the circadian clock protein BMAL1
is an antifibrotic molecule via regulation of glycolysis through the
IDH-1/α-ketoglutarate axis. Strategies that restore reduced BMAL1
could be a therapeutic approach in liver fibrosis–a disease with
high unmet medical need.
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